Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15376518 | 0.93 | HPGDS (0.46) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL15001437 | 0.85 | GPR119 (0.49) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL12810930 | 0.84 | GPR119 (0.48) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL983152 | 0.84 | GPR119 (0.48) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL15531553 | 0.84 | HPGD (0.42) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL19975015 | 0.82 | GPR119 (0.46) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL2103644 | 0.82 | GPR119 (0.45) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL2103641 | 0.82 | GPR119 (0.45) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL2103638 | 0.82 | GPR119 (0.45) | GPR119KDM4EMAPTTHRBHPGDS | |
| SCHEMBL14164236 | 0.81 | GPR119 (0.48) | GPR119KDM4EMAPTTHRBHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198308-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020470-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| WO-2008003770-A1 | PHENYL SUBSTITUTED HETEROARYL-DERIVATIVES AND USE THEREOF AS ANTI-TUMOR AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | GPR119 142/4885KDM4E 4442/4885MAPT 2525/4885 |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | GPR119 376/4885KDM4E 1728/4885MAPT 4140/4885 |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | GPR119 376/4885KDM4E 1728/4885MAPT 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.